간편하게 보는 뉴스는 유니콘뉴스
Boston Oncology and King Fahd Medical City (KFMC) Partner to Advance Localized Cell & Gene Therapy in Saudi Arabia

· 등록일 Aug. 01, 2024 15:30

· 업데이트일 2024-08-02 00:00:19

CAMBRIDGE, MASS. & RIYADH, SAUDI ARABIA--(Business Wire / Korea Newswire)--In a landmark initiative poised to transform healthcare in the Kingdom of Saudi Arabia, Boston Oncology and King Fahd Medical City (KFMC) have signed a Letter of Intent to collaborate on the localization of Cell & Gene Therapy.

Representatives from Boston Oncology and King Fahd Medical City (KFMC), along with His Excellency Eng. Abdulaziz AlRamaih, Deputy Minister of Health for Planning and Development, at the signing ceremony for the partnership to advance localized Cell & Gene Therapy in Saudi Arabia. (Photo: Business Wire) The signing ceremony, attended by His Excellency Eng. Abdulaziz AlRamaih, Deputy Minister of Health for Planning and Development, marks a significant step forward in advancing the Kingdom’s medical capabilities and achieving the ambitious goals set forth in Vision 2030.

A Milestone in Healthcare Transformation

Dr. Fahad Al-Ghofaili, KFMC CEO, expressed his enthusiasm: “Localizing Cell & Gene Therapy in KFMC is an important step to increase local capabilities in advanced treatments and medical technologies, contributing to the goals of the Healthcare Transformation Project.” [Translated from Arabic]

Impact for Patients

Boston Oncology, renowned for its customer-centered model, brings extensive expertise in localizing technology. Laser-focused on the real-world needs of patients and hospitals, Boston Oncology is positioned to provide cutting-edge technologies and Cell & Gene Therapies through this partnership. This collaboration will establish a local treatment option, relieving bottlenecks in therapy provision and improving patient outcomes. The resulting Research & Development and clinical trials will significantly contribute to innovative advancements in the healthcare sector of Saudi Arabia.

Dr. Abdullah Baaj, CEO of Boston Oncology, described the partnership: “KFMC brings world-class clinicians and infrastructure, making it a destination for patients throughout the region. Joining forces to localize Cell & Gene Therapy is a transformative step towards our mission to impact the lives of one billion patients.”

About Boston Oncology Cell & Gene Therapy

Boston Oncology is an innovative life science company with a mission to impact the lives of one billion patients by 2030. With corporate headquarters in Cambridge, Massachusetts, and operations throughout the world, the company is focused on bringing patient-centered solutions and advanced treatment modalities to growing markets. Its new Cell & Gene Therapy entity establishes a fully localized offering to deliver personalized treatments that address the unique genetic profiles of patients. By partnering with leading medical institutions and leveraging leading-edge technologies, Boston Oncology CGT is expanding the company’s legacy of transformative advancements in healthcare.

Learn more at https://bostononcology.com/.

About King Fahd Medical City

King Fahad Medical City (KFMC) in Riyadh, Saudi Arabia, stands as one of the largest and most rapidly expanding medical complexes in the Middle East, with a capacity of 1,200 beds. Operating within the second health cluster, KFMC consists of four hospitals and four specialized medical centers, offering comprehensive healthcare services. Known for its advanced medical technologies and high standard of care, KFMC serves over 30,000 inpatients and 500,000 outpatients annually. The institution is committed to excellence in clinical services, medical education, research, and continuous improvement in healthcare.

Learn more at https://www.kfmc.med.sa/.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240731424463/en/

Website: https://bostononcology.com/ Contact Boston Oncology
Public Relations
[email protected]
This news is a press release provided by Boston Oncology. Korea Newswire follows these editorial guidelines. Boston Oncology News ReleasesSubscribeRSS 보스턴 온콜로지-킹 파흐드 메디컬 시티, 사우디에서 세포·유전자 치료 현지화의 발전 위해 파트너십 체결 보스턴 온콜로지(Boston Oncology)와 킹 파흐드 메디컬 시티(King Fahd Medical City, KFMC)가 세포 및 유전자 치료의 현지화에 대한 협력 의향서에 서명하면서 사우디아라비아의 의료 혁신을 위한 기념비적 이니셔티브를 시작했다. 압둘라지즈 알라마이흐 보건부 기획개발 차관(His Excellency Eng. Abdulazi... 8월 1일 15:30 More News Health Biotechnology Pharmaceutical Alliance Overseas Boston Oncology All News Releases 
인기 기사04.20 05시 기준
쿠알라룸푸르, 인도네시아--(뉴스와이어)--아시아 태평양 지역을 대표하는 해상 연료 물류 기업인 Banle Group (이하 ‘Banle’ 또는 ‘그룹’)의 상장사인 CBL International Limited (이하 ‘회사’ 또는 ‘CBL’)(나스닥: BANL)가 7월 11일 인도에서 최초의 벙커링 서비스를 성공리에 완료했다고 발표했다. 이...
윌밍턴, 델라웨어--(뉴스와이어)--글로벌 인디게임 퍼블리셔 디볼버디지털(Devolver Digital, Inc.)은 자사 퍼블리싱, 올 파서블 퓨처스(All Possible Futures) 개발의 스토리북 어드벤쳐 게임 ‘플럭키 스콰이어(The Plucky Squire)’의 신규 플레이 트레일러를 공개했다. ...
대구--(뉴스와이어)--중소벤처기업부는 미래유망 분야의 중소기업 전문인력 양성을 위해 중소기업 계약학과를 운영할 주관대학을 선정해 중소기업 인력 양성에 기여하고 있다. 대구대학교 본관 전경 ...
서울--(뉴스와이어)--방송인 덱스가 두카티 코리아의 홍보대사로 활동하게 된다. 왼쪽부터 김은석 두카티 코리아 대표와 덱스가 기념 촬영을 하고 있다 ...
성남--(뉴스와이어)--엔씨소프트(대표 김택진, 이하 엔씨(NC))가 ‘2023 다우존스 지속가능경영지수(Dow Jones Sustainability Indices·DJSI)’ Asia Pacific 지수에 국내 게임사 최초로 편입됐다고 14일 밝혔다. 엔씨소프트 판교 R&D 센터 사옥 전경...
서울--(뉴스와이어)--에너지 관리 및 자동화 분야의 디지털 혁신을 선도하고 있는 글로벌 기업 슈나이더 일렉트릭 코리아(www.se.com/kr/ko, 한국지사 대표 김경록)가 지난 1일 특성화 고등학생을 대상으로 장학금을 지원하는 ‘꿈의 날개 프로젝트’를 진행했다고 밝혔다. ...
API
fg
유니콘뉴스는 보도자료 배포 서비스입니다.
여기에 뉴스를 등록하면 언론이 보도하고 널리 배포됩니다.